Pharmaceuticals & Therapeutics

Quebec-based Devonian Health Group plans a NYSE American debut, seeking U.S. capital to advance its promising pipeline of autoimmune disease treatments.

With a new FDA nod for its rare disease drug Joenja, Pharming offers hope to young children, signaling a strategic shift in how we treat complex genetic disorders.

XORTX starts manufacturing its gout drug XORLO™, a pivotal move toward FDA approval. But can it navigate a competitive market and its own financial hurdles?

Activist investor PVG Asset Management is launching a full-scale proxy war to oust Anavex's board, citing a crisis of confidence and stalled progress.

A French biotech takes a critical step to industrialize a promising therapy for LCAT deficiency, navigating the high-stakes regulatory world of biologics.

A €30M investment from the EIB and HERA is backing Ethris's novel mRNA therapeutic. Delivered via nasal spray, it aims to treat chronic respiratory ills and act as a broad-spectrum antiviral.

PhenoNet completes a key trial milestone for its ALS therapy, not with a new molecule, but with a repurposed drug and a savvy regulatory and operational plan.

With Phase 3 data imminent and a new Nasdaq ticker, Helus Pharma is using a key investor conference to frame its novel therapies as the next frontier.

As Cardiol Therapeutics prepares for a key investor conference, it's not just a presentation; it's a test of its strategy to build a durable franchise in heart disease.

An analysis of Chiesi’s H1 results reveals a strategy where strategic acquisitions and deep R&D investment drive both profit and a €6B economic footprint.

An Australian firm is tackling a growing allergy risk in medical implants. Their work on the α-Gal epitope could be key to the future of tissue engineering.

As BioVie seeks FDA approval for a pivotal Phase 3 trial, its novel anti-inflammatory drug could usher in a new era for Parkinson's patients.

A landmark bill in Congress and nationwide walks aim to channel millions into R&D for a genetic disorder affecting 500,000 Americans, creating a new roadmap for a cure.

A breakthrough drug for a rare disease gets a key nod, but its high price tag forces a showdown between patient need and Canada's public purse.

A small biotech is making a bold leap, leveraging its heart disease expertise to tackle Alzheimer's and Parkinson's with a novel class of brain drugs.

A deep dive into PRF Technologies' audacious dual-engine strategy, as it simultaneously pushes for FDA trials and commercializes AI for the green energy grid.

As Claris Bio courts investors, it's not just capital on the line. At stake is a first-of-its-kind eye drop for a rare, blinding disease.

Tangram Therapeutics signals a major strategic push, advancing its novel MASH drug into patient trials while hiring a veteran CDO to steer its pipeline.

The Israeli biotech firm gained crucial FDA feedback for its personalized therapy, NewRal. But in a field laden with failure, is this a true breakthrough?

Northway Biotech's new Vilnius hub isn't just a factory; it's a strategic move to dominate Europe's advanced therapy market. A deep dive into the investment.